{"created":"2023-05-15T16:29:42.895909+00:00","id":570,"links":{},"metadata":{"_buckets":{"deposit":"7ec51a9f-ceed-47b0-8167-b8b06db4c8a7"},"_deposit":{"created_by":2,"id":"570","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"570"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00000570","sets":["29:30:1713167819629:92"]},"author_link":["2959","2958","2956","2952","2954","2955","2957","2953"],"item_3_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"77","bibliographicPageStart":"71","bibliographicVolumeNumber":"63","bibliographic_titles":[{"bibliographic_title":"Acta medica Nagasakiensia"}]}]},"item_3_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Lenvatinib is one of the few therapeutic options available for radioiodine-refractory thyroid cancer. However, the factors that determine the therapeutic outcomes remain unknown.\nMethods: Patients with thyroid carcinoma treated with lenvatinib who had been dead or who had survived for longer than a halfyear\nwere retrospectively compared. We evaluated the clinical parameters when lenvatinib was started, and also studied the tumor volume reduction ratio, the duration until re-growth of the largest metastatic lesion, the thyroglobulin (Tg) reduction rate,and the duration until re-elevation of Tg after lenvatinib between survivors and dead patients.Results: We identified 16 patients, with an average age of 73.1±7.6 yrs and a male-to-female ratio of 5 to 11, who had advanced differentiated thyroid cancer that was treated with lenvatinib. Nine patients had died after 8.9±6.1 months, whereas 7 survived for 13.0±2.0 months after starting lenvatinib. The patients who died were older than the survivors (76.7±6.5 vs. 68.6±6.6 yrs, p=0.03).Malignant pleural effusion (p=0.017) and symptomatic metastatic disease (SMD) (p=0.039) were associated with death in a Kaplan-Meier survival analysis. Age (p=0.012, HR 1.150, CI 1.030-1.320) and SMD (p=0.014, HR 8.069, CI 1.503-61.34) were\nassociated with poor outcome in a multivariate Cox proportional hazard model. The duration until the re-elevation of Tg was\nlonger in survivors than in patients who died (6.43±4.55 vs. 2.17±1.39 months, p=0.025).Conclusions: We identified multiple factors, including SMD, that were related to poor outcomes after lenvatinib treatment. This study suggests that lenvatinib might be started before patients develop SMD.","subitem_description_type":"Abstract"}]},"item_3_description_64":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Acta medica Nagasakiensia, 63(2), pp.71-77; 2020","subitem_description_type":"Other"}]},"item_3_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Nagasaki University School of Medicine"}]},"item_3_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA00508430","subitem_source_identifier_type":"NCID"}]},"item_3_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00016055","subitem_source_identifier_type":"ISSN"}]},"item_3_text_62":{"attribute_name":"sortkey","attribute_value_mlt":[{"subitem_text_value":"03"}]},"item_3_text_63":{"attribute_name":"出版者別言語","attribute_value_mlt":[{"subitem_text_value":"長崎大学医学部"}]},"item_3_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Nakashima, Yomi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ando, Takao"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nozaki, Aya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ito, Ayako"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Horie, Ichiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Imaizumi, Misa"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Usa, Toshiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kawakami, Atsushi"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-18"}],"displaytype":"detail","filename":"ActMed63_71.pdf","filesize":[{"value":"723.5 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ActMed63_71.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/570/files/ActMed63_71.pdf"},"version_id":"eebea0bf-6d2f-427f-89bc-1eea31260b22"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"differentiated thyroid carcinoma","subitem_subject_scheme":"Other"},{"subitem_subject":"lenvatinib","subitem_subject_scheme":"Other"},{"subitem_subject":"prognosis","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Age, Symptomatic Metastatic Disease, and Malignant Pleural Effusion as Predictors of Poor Prognosis in Patients with Differentiated Thyroid Carcinoma Treated with Lenvatinib.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Age, Symptomatic Metastatic Disease, and Malignant Pleural Effusion as Predictors of Poor Prognosis in Patients with Differentiated Thyroid Carcinoma Treated with Lenvatinib."}]},"item_type_id":"3","owner":"2","path":["92"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-03-27"},"publish_date":"2020-03-27","publish_status":"0","recid":"570","relation_version_is_last":true,"title":["Age, Symptomatic Metastatic Disease, and Malignant Pleural Effusion as Predictors of Poor Prognosis in Patients with Differentiated Thyroid Carcinoma Treated with Lenvatinib."],"weko_creator_id":"2","weko_shared_id":2},"updated":"2024-04-16T05:24:37.428730+00:00"}